foscarnet has been researched along with Exanthem in 2 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age." | 7.74 | Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007) |
| "Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age." | 3.74 | Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007) |
| "Skin rash are common in immunocompromised patients, particularly after bone marrow transplantation." | 1.38 | Human Herpesvirus-6 cytopathic inclusions: an exceptional and recognizable finding on skin biopsy during HHV6 reactivation after autologous stem-cell transplantation. ( Battistella, M; Bouaziz, JD; Deau, B; Fornecker, L; Houhou, N; Janin, A; Legoff, J; Roux, J; Thieblemont, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roux, J | 1 |
| Battistella, M | 1 |
| Fornecker, L | 1 |
| Legoff, J | 1 |
| Deau, B | 1 |
| Houhou, N | 1 |
| Bouaziz, JD | 1 |
| Thieblemont, C | 1 |
| Janin, A | 1 |
| Narimatsu, H | 1 |
| Kami, M | 1 |
| Kato, D | 1 |
| Matsumura, T | 1 |
| Murashige, N | 1 |
| Kusumi, E | 1 |
| Yuji, K | 1 |
| Hori, A | 1 |
| Shibata, T | 1 |
| Masuoka, K | 1 |
| Wake, A | 1 |
| Miyakoshi, S | 1 |
| Morinaga, S | 1 |
| Taniguchi, S | 1 |
2 other studies available for foscarnet and Exanthem
| Article | Year |
|---|---|
Human Herpesvirus-6 cytopathic inclusions: an exceptional and recognizable finding on skin biopsy during HHV6 reactivation after autologous stem-cell transplantation.
Topics: Antiviral Agents; Biopsy; Cytopathogenic Effect, Viral; Exanthema; Foscarnet; Hematopoietic Stem Cel | 2012 |
Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
Topics: Adolescent; Adult; Aged; Antigens, Viral; Antiviral Agents; Cord Blood Stem Cell Transplantation; Cy | 2007 |